Skip to content

Fufang Lingze Keli in the Treatment of Type III Chronic Prostatitis (Dampness Heat And Blood Stasis Type): A Single-Center Prospective Cohort Study

Fufang Lingze Keli in the Treatment of Type III Chronic Prostatitis (Dampness Heat And Blood Stasis Type) A Single-Center Prospective Cohort Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025001102
Enrollment
Unknown
Registered
2025-06-03
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Prostatitis

Interventions

Control group:Qianlie Beixi Capsules
Treatment group:Fufang Lingze Keli

Sponsors

The First Affiliated Hospital of Zhejiang Chinese Medical University(Zhejiang Provincial Hospital of Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the NIH-CPSI diagnostic criteria of Western medicine; (43 = NIH-CPSI = 15 points); (2) Those who meet the criteria for chronic prostatitis of damp heat and blood stasis type in traditional Chinese medicine; (3) Age between 18-50 years old; (4) Disease duration = 3 months; (5) Voluntarily participate in treatment and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Diseases that affect urination, such as benign prostatic hyperplasia, prostate cancer, neurogenic bladder, urethral malformation or stenosis, urinary tract stones, severe neurosis, etc; (2) Diseases that cause pain in the perineum due to the combination of prostate abscess, inguinal hernia, pubic inflammation, varicocele, epididymitis, and rectal and colon diseases; (3) Have undergone prostate surgery or laser, radiofrequency, microwave, or ablation treatment; (4) Primary diseases such as cardiovascular diseases, hematopoietic system diseases, and liver and kidney dysfunction; (5) Serious diabetes, mental illness and other serious diseases; (6) Allergic constitution or allergy to multiple drugs; (7) Patients with anxiety, depression (Self Rating Anxiety and Depression Scale) or neurological disorders who cannot express their will, have difficulty moving, or cannot cooperate with treatment and examination; (8) Patients who participate in other clinical trials within one month;

Design outcomes

Primary

MeasureTime frame
NIH chronic prostatitis symptom indexNIH-CPSI;

Secondary

MeasureTime frame
The International Prostate Symptom ScoreIPSS;CQ-D11;

Countries

china

Contacts

Public Contactjin xiao dong

The First Affiliated Hospital of Zhejiang Chinese Medical University(Zhejiang Provincial Hospital of Chinese Medicine)

kingshoulder@163.com13757191398

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026